RE:RE:Oncolytics Biotech® Letter to Shareholders - Update
I suggest that those who talk about pelareorep understand that this drug is an IMMUNE PLATFORM MOLECULE which has the ability to enhance a range of oncology treatments that extends across a broad range of drug classes and indications, which have be detailed in muultiple posts on this message board.
Take a look at ONCY's recent corporate presentation.
https://d1io3yog0oux5.cloudfront.net/_7952fb280dbc7360de640edef99a9055/oncolyticsbiotech/db/300/2536/pdf/Oncolytics+Corporate+Presentation+August.pdf